Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrice Weekly Apolizumab in Relapsed/Refractory CLL/SLL
NCT00089154Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2004
- Primary completion
- Oct 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of apolizumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by National Cancer Institute. Started Aug 2004; status: completed.
02
Drugs
apolizumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00089154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089154.